EMIQ® Research & Clinical Trials


Body Fat Reduction

Obesity, and especially accumulation of visceral fat, is considered strongly related to the pathogenesis of contemporary diseases such as hypertension, diabetes, and dyslipidemia, which are major risk factors for arteriosclerotic diseases. Therefore, it is believed that prevention and reversal of obesity and visceral fat accumulation should aid in the prevention of arteriosclerotic diseases. In this double-blind, placebo-controlled clinical trial of 195 volunteers, three areas of body fat (total fat, internal body cavities, and under the skin) were tested. The group that consumed 275 mg of EMIQ® a day for 12 weeks showed significant fat reduction in all three areas, along with a smaller waist measurement, when compared to the group that was given a placebo.


(Yoshimura, et al., Pharmacol Ther, 2010)


Relief of Allergy Symptoms

In recent years, the incidence of allergic diseases, such as allergic rhinitis, asthma and atopic dermatitis, has been increasing worldwide. Flavonoids, ubiquitously found in fruits, vegetables and teas, are known to have antioxidant as well as anti-allergic effects. In this double-blind, placebo-controlled, 10-week clinical trial with 24 patients, total ocular symptoms were significantly reduced — with and without the use of allergy medication — within the patient group that was given 100 mg of EMIQ® a day.

In this trial, allergy symptoms were evaluated using a scale of 0 = none, 1 = 1―5 episodes, 2 = 6―10 episodes, 3 = 11―20 episodes, 4 = >20 episodes. Patients were also allowed to take allergy medication. The use of medicines was recorded in the symptom dairy with an adjusted score: 0 = no medication, 1 = use of histamine release inhibitors, 2 = use of steroids. Therefore, if a patient felt no symptoms but took a steroid, his symptom score would be O but his symptom + medication score would be 2.

(Hirano, et al., Allegol Int., 2009)


Completed Studies